Role of salidroside in a mouse model of non-alcoholic fatty liver disease： A study based on nicotinamide phosphoribosyltransferase

Rongjun LI; Chunxia XU; Ting ZHANG; Zhihong ZHANG; Lyu WANG

doi:10.12449/JCH240112

Volume 40 Issue 1

Jan. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(1): 64-69

PDF( 1759 KB)

Role of salidroside in a mouse model of non-alcoholic fatty liver disease： A study based on nicotinamide phosphoribosyltransferase

DOI: 10.12449/JCH240112

1.
Department of Spleen，Stomach and Liver Diseases，Luzhou Hospital of Traditional Chinese Medicine，Luzhou，Sichuan 646000，China
2.
Department of General Practice，The Affiliated Hospital of Southwest Medical University，Luzhou，Sichuan 646000，China

Research funding:

Southwest Medical University-Luzhou Traditional Chinese Medicine Hospital Base Project (2017-LH012)

Received Date: 2023-04-09
Accepted Date: 2023-05-26
Published Date: 2024-01-23

Abstract

Abstract

Objective To investigate the protective effect of salidroside against nonalcoholic fatty liver disease （NAFLD） and its mechanism of action. Methods A total of 24 male KM mice were randomly divided into normal group， HFD group， HFD+blank control group， and HFD+salidroside group， with 6 mice in each group. The mice in the normal group were given normal diet， and those in the other groups were given high-fat diet. After 14 weeks of modeling， the mice were given salidroside 100 mg/kg/day by gavage， and related samples were collected at the end of week 22. Enzyme-linked immunosorbent assay was used to measure the serum levels of related biochemical parameters including alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， triglyceride （TG）， total cholesterol （TC）， high-density lipoprotein cholesterol （HDL-C）， and low-density lipoprotein cholesterol （LDL-C）； HE staining and NAFLD activity score （NAS） were used to observe the liver histopathology of mice； Western blot was used to measure the changes in the expression of NAMPT， Sirt1， AMPKα， and SREBP1 in liver tissue. A one-way analysis of variance was used for comparison between multiple groups， and the least significant difference t-test was used for further comparison between two groups. Results Compared with the normal group， the HFD group had obvious steatosis and extensive large lipid droplets in liver tissue， with significant increases in NAS score （P<0.01） and the content of AST， ALT， TG， TC， and LDL-C in peripheral blood （all P<0.05） and a significant reduction in the content of HDL-C （P<0.05）， as well as significant reductions in the expression levels of NAMPT， AMPKα， and Sirt1 in liver tissue （all P<0.05） and a significant increase in the expression level of SERBP1 （P<0.01）. Compared with the HFD group and the HFD+blank control group， the HFD+salidroside group had reductions in the distribution of vacuolar lipid droplets and intralobular inflammation in liver tissue， alleviation of the ballooning degeneration of hepatocytes， significant reductions in NAS score （P<0.01） and the content of AST， ALT， TG， and LDL-C in peripheral blood （all P<0.05）， and a significant increase in the content of HDL-C （P<0.05）， as well as significant increases in the expression levels of NAMPT， AMPKα， and Sirt1 in liver tissue （all P<0.05） and a significant reduction in the expression level of SERBP1 （P<0.01）. Conclusion Salidroside can significantly improve the pathological state of mice with NAFLD induced by high-fat diet and exert a protective effect against NAFLD by increasing the expression of NAMPT， Sirt1， and AMPKα and reducing the expression of SERBP1.
- Nicotinamide Phosphoribosyltransferase,
- Salidroside,
- Non-alcoholic Fatty Liver Disease,
- Mice

FullText(HTML)

References(22)

References

[1]	FAN JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J]. J Gastroenterol Hepatol, 2013, 28( Suppl 1): 11- 17. DOI: 10.1111/jgh.12036.
[2]	LAZARUS JV, MARK HE, VILLOTA-RIVAS M, et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?[J]. J Hepatol, 2022, 76( 4): 771- 780. DOI: 10.1016/j.jhep.2021.10.025.
[3]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
[4]	CHEN SD, ZHOU HH, ZHAO ZX, et al. Jiangzhi and Hepatoprotective effect of salidroside on nonalcoholic fatty liver disease[J]. China J Tradit Chin Med Pharm, 2013, 28( 9): 2701- 2703. 陈少东, 周海虹, 赵正晓, 等. 红景天苷对非酒精性脂肪性肝炎的降脂保肝作用研究[J]. 中华中医药杂志, 2013, 28( 9): 2701- 2703.
[5]	YANG ZR, WANG HF, ZUO TC, et al. Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats[J]. BMC Pharmacol Toxicol, 2016, 17: 16. DOI: 10.1186/s40360-016-0059-8.
[6]	SUN P, SONG SZ, JIANG S, et al. Salidroside regulates inflammatory response in raw 264.7 macrophages via TLR4/TAK1 and ameliorates inflammation in alcohol binge drinking-induced liver injury[J]. Molecules, 2016, 21( 11): 1490. DOI: 10.3390/molecules21111490.
[7]	ZHANG Z, PING J, XU LM. Screening Chinese medicine components for inhibition of human hepatic stellate cell migration[J]. J Clin Hepatol, 2012, 28( 3): 183- 188, 191. DOI: 10.3969/j.issn.1001-5256.2012.03.007. 张展, 平键, 徐列明. 抑制人肝星状细胞株迁移的中药组分筛选[J]. 临床肝胆病杂志, 2012, 28( 3): 183- 188, 191. DOI: 10.3969/j.issn.1001-5256.2012.03.007.
[8]	WANG LF, WANG XN, HUANG CC, et al. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway[J]. Lipids Health Dis, 2017, 16( 1): 82. DOI: 10.1186/s12944-017-0464-z.
[9]	KOBYLIAK N, ABENAVOLI L. The role of liver biopsy to assess non-alcoholic fatty liver disease[J]. Rev Recent Clin Trials, 2014, 9( 3): 159- 169. DOI: 10.2174/1574887109666141216102231.
[10]	ALAMEDDINE A, FAJLOUN Z, BOURREAU J, et al. The cardiovascular effects of salidroside in the Goto-Kakizaki diabetic rat model[J]. J Physiol Pharmacol, 2015, 66( 2): 249- 257.
[11]	WANG SY, ZHAO XX, YANG SX, et al. Salidroside alleviates high glucose-induced oxidative stress and extracellular matrix accumulation in rat glomerular mesangial cells by the TXNIP-NLRP3 inflammasome pathway[J]. Chem Biol Interact, 2017, 278: 48- 53. DOI: 10.1016/j.cbi.2017.10.012.
[12]	FAN XJ, WANG Y, WANG L, et al. Salidroside induces apoptosis and autophagy in human colorectal cancer cells through inhibition of PI3K/Akt/mTOR pathway[J]. Oncol Rep, 2016, 36( 6): 3559- 3567. DOI: 10.3892/or.2016.5138.
[13]	WANG MH, LUO L, YAO LL, et al. Salidroside improves glucose homeostasis in obese mice by repressing inflammation in white adipose tissues and improving leptin sensitivity in hypothalamus[J]. Sci Rep, 2016, 6: 25399. DOI: 10.1038/srep25399.
[14]	GUO Y, WANG SY, YI JJ, et al. Effect of salidroside on apoptosis of CD71⁺ nucleated red blood cells in bone marrow in high altitude polycythemia model rats[J]. J Jilin Univ(Med Ed), 2023, 49( 5): 1174- 1181. DOI: 10.13481/j.1671-587X.20230510. 郭勇, 王生艳, 易静静, 等. 红景天苷对高原红细胞增多症模型大鼠骨髓CD71⁺有核红细胞凋亡的影响[J]. 吉林大学学报(医学版), 2023, 49( 5): 1174- 1181. DOI: 10.13481/j.1671-587X.20230510.
[15]	DAI N, ZOU Y, WANG HF, et al. Inhibitory effect of salidroside on liver oxidative stress in rats with non-alcoholic steatohepatitis[J]. Chin J Pathophysiol, 2013, 29( 9): 1704- 1708. DOI: 10.3969/j.issn.1000-4718.2013.09.030. 戴宁, 邹原, 王慧芳, 等. 红景天苷对非酒精性脂肪性肝炎大鼠肝组织氧化应激的抑制作用[J]. 中国病理生理杂志, 2013, 29( 9): 1704- 1708. DOI: 10.3969/j.issn.1000-4718.2013.09.030.
[16]	ZHANG XR. The mechanism of salidroside regulating glucose and lipid metabolism in type 2 diabetes mice through microRNA[D]. Changchun: Jilin University, 2016. 张新茹. 红景天苷在2型糖尿病小鼠中通过microRNA改善糖脂代谢的机制研究[D]. 长春: 吉林大学, 2016.
[17]	WU TF, LIAO XH, ZHONG BH. Epidemiology of nonalcoholic fatty liver disease in some regions of China[J]. J Clin Hepatol, 2020, 36( 6): 1370- 1373. DOI: 10.3969/j.issn.1001-5256.2020.06.039. 吴挺丰, 廖献花, 钟碧慧. 中国部分地区非酒精性脂肪肝病的流行情况[J]. 临床肝胆病杂志, 2020, 36( 6): 1370- 1373. DOI: 10.3969/j.issn.1001-5256.2020.06.039.
[18]	LI YY, XIE ZY. Advances in the etiology and treatment of non-obese nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37( 2): 452- 457. DOI: 10.3969/j.issn.1001-5256.2021.02.043. 李洋洋, 谢正元. 非肥胖型非酒精性脂肪性肝病的病因及治疗进展[J]. 临床肝胆病杂志, 2021, 37( 2): 452- 457. DOI: 10.3969/j.issn.1001-5256.2021.02.043.
[19]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[20]	RONGVAUX A, SHEA RJ, MULKS MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis[J]. Eur J Immunol, 2002, 32( 11): 3225- 3234. DOI: 3.0.CO;2-L">10.1002/1521-4141(200211)32: 11<3225: AID-IMMU3225>3.0.CO;2-L.
[21]	KOHJIMA M, HIGUCHI N, KATO M, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease[J]. Int J Mol Med, 2008, 21( 4): 507- 511.
[22]	JEON TI, OSBORNE TF. SREBPs: Metabolic integrators in physiology and metabolism[J]. Trends Endocrinol Metab, 2012, 23( 2): 65- 72. DOI: 10.1016/j.tem.2011.10.004.

Relative Articles

[1]	Linqi HOU, Zhiyi WANG, Xin ZHAO, Jie ZHANG, Wenting MA, Xuling LIU, Wei ZHANG, Le TAO, Cheng LIU, Liu WU. Therapeutic effect of Xiayuxue decoction on a mouse model of nonalcoholic fatty liver disease induced by high-fat diet and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(4): 712-719. doi: 10.12449/JCH240412
[2]	Xiangyu ZHU, Yong JIN. Protective effect of Genistein against nonalcoholic fatty liver disease in ovariectomized mice and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(4): 706-711. doi: 10.12449/JCH240411
[3]	Chaorong TAN, Xiaopiao LI, Junyan RAN, Ying XIONG, Shanggao LIAO, Jinjuan ZHANG, Xun HE. Role and mechanism of action of phytoestrogen biochanin A in improving liver fibrosis in ovariectomized mice[J]. Journal of Clinical Hepatology, 2024, 40(1): 76-82. doi: 10.12449/JCH240114
[4]	Tingting SHEN, Gerui ZHU, Fan WANG, Xin SUN, Kai HUANG, Yuan PENG, Yanyan TAO, Chenghai LIU. Role of glutathione transferase in nonalcoholic fatty liver disease: An analysis based on gene expression profile[J]. Journal of Clinical Hepatology, 2023, 39(1): 89-96. doi: 10.3969/j.issn.1001-5256.2023.01.014
[5]	Yekai ZONG, Jiangkai LIU. Association between the sirtuin family of deacetylases and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(10): 2357-2361. doi: 10.3969/j.issn.1001-5256.2022.10.030
[6]	Hao TANG, Yixiao YIN, Wei LIU, Yi FANG, Jun WANG, Yiyang HU, Jinghua PENG. Effects of Xuefu Zhuyu decoction and its extracts on a mouse model of nonalcoholic fatty liver disease induced by high-fat diet[J]. Journal of Clinical Hepatology, 2022, 38(12): 2728-2737. doi: 10.3969/j.issn.1001-5256.2022.12.010
[7]	Hao XU, Bai RUAN, Zhiwen LI, Zhiqiang FANG, Lin WANG, Kefeng DOU. Establishment of a mouse model of vascular endothelial-mesenchymal transdifferentiation genetic tracing and its role in liver fibrosis studies[J]. Journal of Clinical Hepatology, 2022, 38(4): 832-836. doi: 10.3969/j.issn.1001-5256.2022.04.018
[8]	Mengke WANG, Shousheng LIU, Xueru CHU, Yifen WANG, Yongning XIN. Construction of Pnpla3 I148M and Tm6sf2 E167K double mutant mouse model[J]. Journal of Clinical Hepatology, 2022, 38(8): 1784-1789. doi: 10.3969/j.issn.1001-5256.2022.08.013
[9]	Jie ZHANG, Xuefeng MA, Yifen WANG, Mengke WANG, Likun ZHUANG, Shousheng LIU, Yongning XIN. Hepatocyte-specific TM6SF2 knockout aggravates hepatic steatosis in mice with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2612-2616. doi: 10.3969/j.issn.1001-5256.2021.11.024
[10]	Zhang Dan, Zhou Bo, Deng Yi, Wen Yu, Lu: JunYan, Wang JinXiang, Geng ZuoTao, Luo SuFeng, Ying YunYan, Wen DaiYan, Shi ChunJing, Pu GuangYu, Jiang Xin, Ma LanQing. Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 829-834. doi: 10.3969/j.issn.1001-5256.2020.04.024
[11]	Yang AiTing, Yan XuZhen, Zhao WenShan, Li WeiYu, Chen Wei, You Hong. Molecular mechanism of elastin and its regulatory factors on the formation and reversal of liver fibrosis in a mouse model of liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1514-1519. doi: 10.3969/j.issn.1001-5256.2020.07.014
[12]	Ren ShiPing, Ma ZhenQi, Wang XueHong. Association of visfatin with thyroid dysfunction in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1382-1385. doi: 10.3969/j.issn.1001-5256.2020.06.042
[13]	Wang XiaoXiao, Zhao Jie, Li XiaoHe, Rao HuiYing, Wei Lai, Liu Feng. Value of second harmonic generation/two-photon excitation fluorescence in quantitative evaluation of liver fibrosis in mice with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(8): 1786-1790. doi: 10.3969/j.issn.1001-5256.2019.08.027
[14]	Zhao XiaoFang, Tang YouMing, Xu XinJie, Tang YanFang, Liu XuDong, Lu: Ping, Zhao ZhuangZhi. Effect on JNK1 gene silencing on the expression of high-molecular-weight adiponectin in mice with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(10): 2257-2260. doi: 10.3969/j.issn.1001-5256.2019.10.025
[15]	Wang Xin, Hu YiYang, Feng Qin. Current status of research on mouse models of nonalcoholic fatty liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1865-1869. doi: 10.3969/j.issn.1001-5256.2019.08.049
[16]	Mai JingYin, Chen TianYang, Cheng Yang. Changes in microRNA expression profile in the liver of mice with nonalcoholic fatty liver disease induced by high-fat diet[J]. Journal of Clinical Hepatology, 2017, 33(12): 2372-2375. doi: 10.3969/j.issn.1001-5256.2017.12.023
[17]	Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028
[18]	Zhu HuiJia, Hou YiJun, Yuan KaiZhen, Xu LanMan, Lin Zhuo, Chen YongPing. Inhibitory effect of Anfate on expression of TGFβ1 /Smad2 signaling pathway in treatment of hepatic fibrosis in mice[J]. Journal of Clinical Hepatology, 2014, 30(4): 335-339. doi: 10.3969/j.issn.1001-5256.2014.04.012
[19]	Yang Li, Feng AiDong, Zheng HaoJie, Dai ErHei. Effects of Ruangan Huajian granules on mRNA expression of MMP- 13 and TIMP- 1 in liver tissue among C57 mice with hepatic fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(4): 340-343. doi: 10.3969/j.issn.1001-5256.2014.04.013
[20]	Sun KeYan, Teng Fei, Guo WenYuan, Liu Fang, Fu ZhiRen. Protective role of β- catenin gene in hepatic ischemia- reperfusion injury among mice and its mechanism[J]. Journal of Clinical Hepatology, 2013, 29(10): 787-789. doi: 10.3969/j.issn.1001-5256.2013.10.016

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (420) PDF downloads(38)

Role of salidroside in a mouse model of non-alcoholic fatty liver disease： A study based on nicotinamide phosphoribosyltransferase

DOI: 10.12449/JCH240112

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of salidroside in a mouse model of non-alcoholic fatty liver disease： A study based on nicotinamide phosphoribosyltransferase

DOI: 10.12449/JCH240112

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content